Eupraxia Pharma (EPRX): When Painful Swallowing Nearly Disappeared, Investors Took Notice
In Eupraxia Pharmaceuticals’ RESOLVE Phase 1b/2a trial, moderate-to-severe odynophagia in the highest-dose cohorts fell from 62% at baseline to 25% from weeks 24 through 52, and no patient reported severe pain at either checkpoint.
Sep 12, 2026 ·
Yahoo Finance



















